The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
Open accessAbstract
Parkinson’s disease (PD) is a common neurodegenerative disorder. While a number of nonmotor manifestations arise, the typical clinical features involve a movement disorder consisting of bradykinesia, resting tremor, and rigidity, with postural instability occurring at a later stage. The cause of PD is not known, but a number of genetic risk factors have now been characterized, as well as several genes which cause rare familial forms of PD. Environmental influences such as smoking, caffeine consumption, and pesticide exposure have been postulated to alter the risk of PD development, although the role of these remains unclear. The movement disorder arises due to the loss of dopaminergic neurons of the substantia nigra pars compacta, with the pathological hallmark being intracellular aggregates of α-synuclein, in the form of Lewy bodies and Lewy neurites. Several processes have been implicated in PD, including mitochondrial dysfunction, defective protein clearance mechanisms, and neuroinflammation, but the way in which these factors interact remains incompletely understood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“Finally, during stages 5 and 6, the key feature is the involvement of the entire neocortex and high-order areas, including the prefrontal cortex and primary sensory and motor areas (84, 87).”
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 7×
“Point mutations in two more PARK genes impair the function of either parkin (PARK2) (58) or PINK1 (PARK6) (60), both of which are involved in the autophagic turnover of mitochondria (52).”
InfluentialChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 1×
“Degeneration in those systems is thought to account for some of the non-motor symptoms of PD that do not respond well to dopamine replacement therapies (79).”
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895 · cited 2×
“Other genetic risk factors include the major histocompatibility complex, class II (HLA-DQB1) (42) and the gene encoding the protein tau, MAPT (43), among others.”
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
(1998) · Europe PMC (PubMed Central) · Cited by 1,594
Rotenone, Paraquat, and Parkinson’s Disease
Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., Marras, C., Bhudhikanok, G. S., Kasten, M., Chade, A. R., et al. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1002839 · Cited by 1,475
In vivo demonstration that α-synuclein oligomers are toxic
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100976108 · Cited by 1,463
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Variable expression of Parkinson's disease: A base‐line analysis of the DAT ATOP cohort
Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., et al. (1990) · Neurology · doi:10.1212/wnl.40.10.1529 · Cited by 1,285
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263 · cited 1×
“Native α-synuclein in the brain is mostly unfolded without a defined tertiary structure (109), although in aqueous solutions it can be present in stable tetramers that resist aggregation (110).”
Nicklas, W. J., Vyas, I., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,262
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 1×
“minocycline pre- and post-neurotoxic insult led to a significant attenuation of DA cell death in the SNpc, suggesting that microglia-induced inflammatory processes may be contributing to the degeneration of these cells (152, 153).”
Eliezer, D., Kutluay, E., Bussell, R., & Browne, G. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4538 · Cited by 1,090
Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G., & Anandatheerthavarada, H. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710012200 · Cited by 1,080
Parkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012
Martinez‐Martin, P., Rodriguez‐Blazquez, C., Kurtis, M. M., Chaudhuri, K. R., & on Behalf of the NMSS Validation Group (2011) · Movement Disorders · doi:10.1002/mds.23462 · Cited by 989
Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White III, C. L., Akiyama, H., Caviness, J. N., Shill, H. A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0664-3 · Cited by 911
Parkinson's Disease and Parkinsonism: Neuropathology
Dickson, D. W. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009258 · Cited by 847
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818
Vagotomy and subsequent risk of Parkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Iranzo, A., Tolosa, E., Gelpi, E., Molinuevo, J. L., Valldeoriola, F., Serradell, M., Sanchez-Valle, R., Vilaseca, I., Lomeña, F., Vilas, D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70056-5 · Cited by 723
G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome
Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Dürr, A., Melki, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23894 · Cited by 711
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 3×
“Regular tea drinkers also have been reported to have a lower risk of developing PD (29).”
Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study
Schrag, A., Horsfall, L., Walters, K., Noyce, A., & Petersen, I. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70287-x · Cited by 674
Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease
Appel‐Cresswell, S., Vilarino‐Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu‐Tu, C., Trinh, J., et al. (2013) · Movement Disorders · doi:10.1002/mds.25421 · Cited by 667
Proteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653
Epidemiology of parkinson’s disease
Tanner, C. M., & Goldman, S. M. (1996) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70259-0 · Cited by 640
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C. T., Burton, E. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3634 · Cited by 619
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 612
Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
Compta, Y., Parkkinen, L., O'Sullivan, S. S., Vandrovcova, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., et al. (2011) · Brain · doi:10.1093/brain/awr031 · Cited by 583
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
Altered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease
Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., Gasser, T., Wszolek, Z., Müller, T., Bornemann, A., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi215 · Cited by 568
Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains
Alvarez-Erviti, L., Rodriguez-Oroz, M. C., Cooper, J. M., Caballero, C., Ferrer, I., Obeso, J. A., & Schapira, A. H. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.198 · Cited by 554
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease
Pan, T., Kondo, S., Le, W., & Jankovic, J. (2008) · Brain · doi:10.1093/brain/awm318 · Cited by 546
The genetics of Parkinson disease
Deng, H., Wang, P., & Jankovic, J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.12.007 · Cited by 530
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990
Bower, J. H., Maraganore, D. M., McDonnell, S. K., & Rocca, W. A. (1999) · Neurology · doi:10.1212/wnl.52.6.1214 · Cited by 511
PINK1 mutations are associated with sporadic early‐onset parkinsonism
Valente, E. M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A. E., Caputo, V., Romito, L., Albanese, A., Dallapiccola, B., & Bentivoglio, A. R. (2004) · Annals of Neurology · doi:10.1002/ana.20256 · Cited by 505
Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., Albanese, A., & Wood, N. W. (2001) · The American Journal of Human Genetics · doi:10.1086/319522 · Cited by 493
Prevalence of Parkinson's disease in the elderly: The Rotterdam Study
de Rijk, M. C., Breteler, M. M. B., Graveland, G. A., Ott, A., Grobbee, D. E., van der Meche, F. G. A., & Hofman, A. (1995) · Neurology · doi:10.1212/wnl.45.12.2143 · Cited by 488
Characterization of PLA2G6 as a locus for dystonia‐parkinsonism
Paisan‐Ruiz, C., Bhatia, K. P., Li, A., Hernandez, D., Davis, M., Wood, N. W., Hardy, J., Houlden, H., Singleton, A., & Schneider, S. A. (2009) · Annals of Neurology · doi:10.1002/ana.21415 · Cited by 480
Synuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474 · cited 1×
“For instance, in primary cultures, α-synuclein mediates a dose-dependent activation of microglia (154).”
Mitochondrial Dysfunction in Parkinson’s Disease
Moon, H. E., & Paek, S. H. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.2.103 · Cited by 455
Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
Lee, H.-J., Khoshaghideh, F., Patel, S., & Lee, S.-J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3809-03.2004 · Cited by 445
Lesage, S., Drouet, V., Majounie, E., Deramecourt, V., Jacoupy, M., Nicolas, A., Cormier-Dequaire, F., Hassoun, S. M., Pujol, C., Ciura, S., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.01.014 · Cited by 434
Karpinar, D. P., Balija, M. B. G., Kügler, S., Opazo, F., Rezaei‐Ghaleh, N., Wender, N., Kim, H., Taschenberger, G., Falkenburger, B. H., Heise, H., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.257 · Cited by 432
The spectrum of nonmotor symptoms in early Parkinson disease
Khoo, T. K., Yarnall, A. J., Duncan, G. W., Coleman, S., O’Brien, J. T., Brooks, D. J., Barker, R. A., & Burn, D. J. (2013) · Neurology · doi:10.1212/wnl.0b013e31827deb74 · Cited by 427
Chu, Y., Dodiya, H., Aebischer, P., Olanow, C. W., & Kordower, J. H. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.023 · Cited by 421
Hunot, S., Dugas, N., Faucheux, B., Hartmann, A., Tardieu, M., Debré, P., Agid, Y., Dugas, B., & Hirsch, E. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03440.1999 · Cited by 408
Pooled Analysis of Tobacco Use and Risk of Parkinson Disease
Ritz, B., Ascherio, A., Checkoway, H., Marder, K. S., Nelson, L. M., Rocca, W. A., Ross, G. W., Strickland, D., Van Den Eeden, S. K., & Gorell, J. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.990 · Cited by 370
FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome
Fonzo, A. D., Dekker, M. C. J., Montagna, P., Baruzzi, A., Yonova, E. H., Guedes, L. C., Szczerbinska, A., Zhao, T., Dubbel-Hulsman, L. O. M., Wouters, C. H., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000338144.10967.2b · Cited by 364
Parkkinen, L., Pirttilä, T., & Alafuzoff, I. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0346-6 · Cited by 354
Greffard, S., Verny, M., Bonnet, A.-M., Beinis, J.-Y., Gallinari, C., Meaume, S., Piette, F., Hauw, J.-J., & Duyckaerts, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.584 · Cited by 354
Platelet mitochondria function in Parkinson's disease
Krige, D., Carroll, M. T., Cooper, J. M., Marsden, C. D., Schapira, A. H. V., & (The Royal Kings Queens Parkinson Disease Research Group) (1992) · Annals of Neurology · doi:10.1002/ana.410320612 · Cited by 352
He, Y., Appel, S., & Le, W. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02681-6 · Cited by 348
Properties of native brain α-synuclein
Burré, J., Vivona, S., Diao, J., Sharma, M., Brunger, A. T., & Südhof, T. C. (2013) · Nature · doi:10.1038/nature12125 · Cited by 339
Bloch, A., Probst, A., Bissig, H., Adams, H., & Tolnay, M. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00727.x · Cited by 330
Bedford, L., Hay, D., Devoy, A., Paine, S., Powe, D. G., Seth, R., Gray, T., Topham, I., Fone, K., Rezvani, N., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2218-08.2008 · Cited by 327
Use of ibuprofen and risk of Parkinson disease
Gao, X., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2011) · Neurology · doi:10.1212/wnl.0b013e31820f2d79 · Cited by 321
Mutation in the SYNJ1 Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism
Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G. J., Graafland, J., Wu, B., Xu, F., Erro, R., Amboni, M., et al. (2013) · Human Mutation · doi:10.1002/humu.22373 · Cited by 320
Professional exposure to pesticides and Parkinson disease
Elbaz, A., Clavel, J., Rathouz, P. J., Moisan, F., Galanaud, J., Delemotte, B., Alpérovitch, A., & Tzourio, C. (2009) · Annals of Neurology · doi:10.1002/ana.21717 · Cited by 317
DNAJC13 mutations in Parkinson disease
Vilariño-Güell, C., Rajput, A., Milnerwood, A. J., Shah, B., Szu-Tu, C., Trinh, J., Yu, I., Encarnacion, M., Munsie, L. N., Tapia, L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt570 · Cited by 313
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE‐PD)
Williams‐Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J. R., Cummins, G. A., Duncan, G. W., Khoo, T. K., Burn, D. J., et al. (2016) · Movement Disorders · doi:10.1002/mds.26563 · Cited by 304
Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
Xilouri, M., Brekk, O. R., & Stefanis, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8341-2 · Cited by 299
Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease
Chartier-Harlin, M.-C., Dachsel, J. C., Vilariño-Güell, C., Lincoln, S. J., Leprêtre, F., Hulihan, M. M., Kachergus, J., Milnerwood, A. J., Tapia, L., Song, M.-S., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.08.009 · Cited by 299
Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S., & Selkoe, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.545749 · Cited by 279
Seeding induced by α‐synuclein oligomers provides evidence for spreading of α‐synuclein pathology
Danzer, K. M., Krebs, S. K., Wolff, M., Birk, G., & Hengerer, B. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06324.x · Cited by 276
Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia
Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., Turkheimer, F. E., & Brooks, D. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.255 · Cited by 274
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., & Lees, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000310812.43352.66 · Cited by 271
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease
Goris, A., Williams‐Gray, C. H., Clark, G. R., Foltynie, T., Lewis, S. J. G., Brown, J., Ban, M., Spillantini, M. G., Compston, A., Burn, D. J., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21192 · Cited by 270
MUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET
Sidransky, E., Samaddar, T., & Tayebi, N. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b28601 · Cited by 259
Protein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
Parkinson's disease subtypes: lost in translation?
Marras, C., & Lang, A. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303455 · Cited by 253
Breckenridge, C. B., Berry, C., Chang, E. T., Sielken, R. L., & Mandel, J. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151841 · Cited by 239
Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study
Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Neurology · doi:10.1212/wnl.55.9.1350 · Cited by 234
Ascherio, A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh312 · Cited by 232 · cited 1×
“As estrogen competitively inhibits caffeine metabolism, interactions between estrogen and caffeine may explain in part why PD risk is dependent on hormone replacement therapy in postmenopausal women (31, 32).”
McNaught, K. S. P., Belizaire, R., Jenner, P., Olanow, C. W., & Isacson, O. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00296-3 · Cited by 232
A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders
Jellinger, K. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.006 · Cited by 232
Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease
Bindoff, L. A., Birch-Machin, M. A., Cartlidge, N. E. F., Parker, W. D., & Turnbull, D. M. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90311-t · Cited by 229
Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M., & Pearce, R. K. B. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00923.x · Cited by 222
Prospective Study of Cigarette Smoking and the Risk of Developing Idiopathic Parkinson's Disease
Grandinetti, A., Morens, D. M., Reed, D., & MacEachern, D. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116960 · Cited by 220
Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J. N., & Sidhu, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.06.017 · Cited by 211
Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases
Pletnikova, O., West, N., Lee, M. K., Rudow, G. L., Skolasky, R. L., Dawson, T. M., Marsh, L., & Troncoso, J. C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.10.006 · Cited by 209
The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203 · cited 1×
“An epidemiological study from Denmark has revealed that a full truncal vagotomy is associated with a reduced risk of subsequent PD (96), leading to recent interest in the possible role of the gut–brain axis in the pathogenesis of PD (97).”
BackgroundAltered Proteins in the Aging Brain
Elobeid, A., Libard, S., Leino, M., Popova, S. N., & Alafuzoff, I. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw002 · Cited by 202
Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset
Nichols, W. C., Pankratz, N., Marek, D. K., Pauciulo, M. W., Elsaesser, V. E., Halter, C. A., Rudolph, A., Wojcieszek, J., Pfeiffer, R. F., & Foroud, T. (2009) · Neurology · doi:10.1212/01.wnl.0000327823.81237.d1 · Cited by 202
Williams, D. R., Hadeed, A., al‐Din, A. S. N., Wreikat, A., & Lees, A. J. (2005) · Movement Disorders · doi:10.1002/mds.20511 · Cited by 197
Genetic basis of Parkinson's disease: inheritance, penetrance, and expression
Gasser, T. (2011) · The Application of Clinical Genetics · doi:10.2147/tacg.s11639 · Cited by 197
DNAJC6 Mutations Associated With Early‐Onset Parkinson's Disease
Olgiati, S., Quadri, M., Fang, M., Rood, J. P. M. A., Saute, J. A., Chien, H. F., Bouwkamp, C. G., Graafland, J., Minneboo, M., Breedveld, G. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24553 · Cited by 197
Cigarette smoking and the incidence of Parkinson's disease in two prospective studies
Hernán, M. A., Zhang, S. M., Rueda‐DeCastro, A. M., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2001) · Annals of Neurology · doi:10.1002/ana.10028 · Cited by 191
Parkinson's Disease Is Not Simply a Prion Disorder
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1787-16.2017 · Cited by 188
Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease
Lautier, C., Goldwurm, S., Dürr, A., Giovannone, B., Tsiaras, W. G., Pezzoli, G., Brice, A., & Smith, R. J. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.015 · Cited by 178
Proteomic identification of novel proteins associated with Lewy bodies
Xia, Q. (2008) · Frontiers in Bioscience · doi:10.2741/2973 · Cited by 176
Post-translational modification of α-synuclein in Parkinson׳s disease
Barrett, P. J., & Timothy Greenamyre, J. (2015) · Brain Research · doi:10.1016/j.brainres.2015.06.002 · Cited by 174
Lashley, T., Holton, J. L., Gray, E., Kirkham, K., O’Sullivan, S. S., Hilbig, A., Wood, N. W., Lees, A. J., & Revesz, T. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0336-0 · Cited by 172
Morphometry of the human substantia nigra in ageing and Parkinson’s disease
Rudow, G., O’Brien, R., Savonenko, A. V., Resnick, S. M., Zonderman, A. B., Pletnikova, O., Marsh, L., Dawson, T. M., Crain, B. J., West, M. J., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0352-8 · Cited by 171
Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.
Loeffler, D. A., Camp, D. M., & Conant, S. B. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-29 · Cited by 168
The Ubiquitin-Proteasome System in Neurodegeneration
McKinnon, C., & Tabrizi, S. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5802 · Cited by 165
Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects
Beach, T. G., Carew, J., Serrano, G. E., Adler, C. H., Shill, H. A., Sue, L. I., Sabbagh, M. N., Akiyama, H., & Cuenca, N. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.04.027 · Cited by 161
Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
Ritz, B., Lee, P.-C., Lassen, C. F., & Arah, O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000879 · Cited by 160
Ma, S. Y., Röyttä, M., Rinne, J. O., Collan, Y., & Rinne, U. K. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00100-7 · Cited by 160
Risk factors for parkinson’s disease: The leisure world cohort study
Paganini-Hill, A. (2001) · Neuroepidemiology · doi:10.1159/000054770 · Cited by 159
Nishikawa, K., Li, H., Kawamura, R., Osaka, H., Wang, Y.-L., Hara, Y., Hirokawa, T., Manago, Y., Amano, T., Noda, M., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00555-2 · Cited by 158
Prevalence, incidence, and mortality of PD
Chen, R.-T., Chang, S.-S., Su, C., Chen, T. H. H., Yen, M. F., Wu, H. M., Chen, Z., & Liou, H. (2001) · Neurology · doi:10.1212/wnl.57.9.1679 · Cited by 156
Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease
Tanji, K., Mori, F., Kakita, A., Takahashi, H., & Wakabayashi, K. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.022 · Cited by 152
Xu, K., Xu, Y., Brown-Jermyn, D., Chen, J., Ascherio, A., Dluzen, D. E., & Schwarzschild, M. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3008-05.2006 · Cited by 146
Progression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145 · cited 1×
“Finally, during stages 5 and 6, the key feature is the involvement of the entire neocortex and high-order areas, including the prefrontal cortex and primary sensory and motor areas (84, 87).”
Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity
Monte, D. A. D., Sandy, M. S., Ekström, G., & Smith, M. T. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)91210-6 · Cited by 145
Striatal β-Amyloid Deposition in Parkinson Disease With Dementia
Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M., & Pearce, R. K. B. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816362aa · Cited by 145
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Kalia, L. V., Brotchie, J. M., & Fox, S. H. (2012) · Movement Disorders · doi:10.1002/mds.25273 · Cited by 140
Interaction between pathogenic proteins in neurodegenerative disorders
Jellinger, K. A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01507.x · Cited by 140
Alpha‐Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism
Duka, T., Rusnak, M., Drolet, R. E., Duka, V., Wersinger, C., Goudreau, J. L., & Sidhu, A. (2006) · The FASEB Journal · doi:10.1096/fj.06-6092com · Cited by 121
A Swedish family with de novo α-synuclein A53T mutation: Evidence for early cortical dysfunction
Puschmann, A., Ross, O. A., Vilariño‐Güell, C., Lincoln, S., Kachergus, J. M., Cobb, S. A., Lindquist, S. G., Nielsen, J. E., Wszołek, Z. K., Farrer, M. J., et al. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.06.007 · Cited by 105
Ruffmann, C., Calboli, F. C. F., Bravi, I., Gveric, D. O., Curry, L. K., de Smith, A. J., Pavlou, S., Buxton, J. L., Blakemore, A. I. F., Takousis, P., et al. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12294 · Cited by 105
Parkin Directly Modulates 26S Proteasome Activity
Um, J. W., Im, E., Lee, H. J., Min, B., Yoo, L., Yoo, J., Lübbert, H., Stichel-Gunkel, C. C., Cho, H.-S., Yoon, J. B., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2862-09.2010 · Cited by 92
Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family
Wider, C. W., Skipper, L. M., Solida, A., Brown, L., Farrer, M. J., Dickson, D. W., Wszołek, Z. K., & Vingerhoets, F. J. G. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.11.013 · Cited by 81
Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats
Zeng, B., Bukhatwa, S., Hikima, A., Rose, S., & Jenner, P. G. (2006) · Annals of Neurology · doi:10.1002/ana.20932 · Cited by 76
Bordia, T., McGregor, M. M., Papke, R. L., Decker, M. W., McIntosh, J. M., & Quik, M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.09.015 · Cited by 76
Association of the human leucocyte antigen region with susceptibility to Parkinson's disease
Saiki, M., Baker, A., Williams‐Gray, C. H., Foltynie, T., Goodman, R. S., Taylor, C. J., Compston, D. A. S., Barker, R., Sawcer, S. J., & Goris, A. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.162883 · Cited by 74
Srinivasan, R., Henley, B. M., Henderson, B. J., Indersmitten, T., Cohen, B. N., Kim, C. H., McKinney, S. L., Deshpande, P., Xiao, C., & Lester, H. A. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2126-15.2016 · Cited by 68
Williams‐Gray, C. H., & Worth, P. F. (2016) · Medicine · doi:10.1016/j.mpmed.2016.06.001 · Cited by 64
Duka, T., & Sidhu, A. (2006) · Neurotoxicity Research · doi:10.1007/bf03033329 · Cited by 56
Zeng, B. ‐., Iravani, M. M., Lin, S., Irifune, M., Kuoppamäki, M., Al‐Barghouthy, G., Smith, L., Jackson, M. J., Rose, S., Medhurst, A. D., et al. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04718.x · Cited by 41
Ullrich, C., Mlekusch, R., Kuschnig, A., Marksteiner, J., & Humpel, C. (2010) · Current Alzheimer Research · doi:10.2174/156720510792231766 · Cited by 29
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Research works printed but not linked: 2
- 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F · DOI
- 10.1289/ehp.1002839 · DOI · Paper page
Cited by
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
Microglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Dentamaro, V., Impedovo, D., Musti, L., Pirlo, G., & Taurisano, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-70165-4 · Cited by 116
Lorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
Metadata
- Authors
- John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N.
- Venue
- Parkinson’s Disease: Pathogenesis and Clinical Aspects
- Publisher
- Codon Publications
- Published
- 2018-12-22
- Pages
- 3-26
- OpenAlex
- W2906486676
- Cited by
- 507
- References
- 157
- FWCI
- 68.06
- Type
- book chapter
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.